



Management

[About Us](#)

[Management](#)

[Advisory Board](#)

[Career Opportunities](#)

Management


Gary A. Reys – Chief Executive Officer, President and Chairman.

Mr. Reys brings over 30 years of experience with both international Fortune 100 and 500 publicly traded companies and emerging-growth companies in the pharmaceutical, biotechnology and medical device fields. He held executive positions with Pfizer and with Rhone Poulenc Rorer (now Aventis), North America. Mr. Reys was one of the pioneers in the generic pharmaceutical industry as part of a five member founding executive team which formed Schein Pharmaceutical, taking the company through an IPO and the acquisition by Bayer AG. Mr. Reys served as Vice President of Business Development for Goldline Laboratories and then as Vice President of SuperPharm Laboratories, a subsidiary division, positioning the company for the acquisition by IVAX, an international pharmaceutical holding company (now Teva Pharmaceutical). Mr. Reys served as Executive Vice President and Chief Financial Officer of IBV Technologies, a division of the McKesson Corporation. Mr. Reys also served as Chief Executive Officer and President of Genespan, a cell expansion and DNA biotechnology company which was acquired by CellCyte. He served as Chief Executive Officer, President and Chief Financial Officer for Clear Medical where he positioned the company as the first FDA approved high-level disinfectant re-processor of medical devices. Most recently, he served as the President and Chief Executive Officer of Cennapharm, a biopharmaceutical company which he co-founded, taking the Company from conception to early human clinical trials in 18 months. Mr. Reys attended the University of Washington where he majored in finance, later receiving a CPA designate. Mr. Reys is a past member of the Washington Society of Certified Public Accountants. He also serves as a member of the University of Washington's Graduate School, M.B.A. Mentor Advisory Board.



Dr. Ronald W. Berninger, Ph.D., – Executive Vice President and Chief Scientific Officer

Dr. Berninger has over 20 years experience in building research teams and moving products from R&D to manufacturing and into the



marketplace. Dr. Berninger served as Vice President and Director of R&D and QA/Regulatory for Genespan Corporation and also for Cennapharm Corporation. In both positions he was responsible for formulation of drugs and building the infrastructure for R&D, Quality, Regulatory, and Documentation. Prior to that, Dr. Berninger served as Senior Scientist and Head of Biochemistry at CellPro, a stem cell company. As a member of the award winning Ceprate™ SC Concentrator development team, he was instrumental in establishing the first FDA approved process for purification, biotinylation and formulation of a CD34 IgM monoclonal antibody for purification of stem cells. Dr. Berninger also played a vital role in defining the chemistry for the affinity gel employed in the Ceprate™ product used for cancer and gene therapy applications. Dr. Berninger served as Senior Scientist for NeoRx Corporation where he used his expertise in chemistry to play a pivotal role in purifying and chemically modifying monoclonal antibodies to target tumor cells in diagnostic and clinical applications.



Dr. Berninger served as Assistant Professor at the Tufts University School of Medicine from 1980 to 1986. Prior to that appointment, Dr. Berninger was a Fellow, Instructor and Assistant Professor at the John Hopkins University School of Medicine from 1975 to 1980. He received his B.S. degree in Chemistry from Drexel University in 1968 and in 1972 was awarded a Ph.D. in Organic Chemistry from the University of Pittsburgh. Dr. Berninger has received numerous awards, patents and honors for his scientific discoveries and has over 70 scientific publications.

 [More](#)